Patient characteristics at study entrance
| Patient no. . | Autoimmune disease . | Sex . | Age, y . | Time since IA, mo . | Immunosuppressive therapy, mg/day . | ||
|---|---|---|---|---|---|---|---|
| PRE . | MM . | CyA . | |||||
| 1 | EO | F | 59 | 4 | — | — | — |
| 2 | MG | F | 30 | 43 | 10 | 2000 | — |
| 3 | SLE | F | 28 | 6 | 20 | 500 | 250 |
| 4 | MG | F | 27 | 57 | — | 2000 | — |
| 5 | EO | F | 49 | 14 | — | — | — |
| 6 | SLE | F | 37 | 19 | 7.5 | — | — |
| 7 | EO | M | 54 | 4 | — | — | — |
| 8 | GB | F | 74 | 0 | 15 | — | — |
| Patient no. . | Autoimmune disease . | Sex . | Age, y . | Time since IA, mo . | Immunosuppressive therapy, mg/day . | ||
|---|---|---|---|---|---|---|---|
| PRE . | MM . | CyA . | |||||
| 1 | EO | F | 59 | 4 | — | — | — |
| 2 | MG | F | 30 | 43 | 10 | 2000 | — |
| 3 | SLE | F | 28 | 6 | 20 | 500 | 250 |
| 4 | MG | F | 27 | 57 | — | 2000 | — |
| 5 | EO | F | 49 | 14 | — | — | — |
| 6 | SLE | F | 37 | 19 | 7.5 | — | — |
| 7 | EO | M | 54 | 4 | — | — | — |
| 8 | GB | F | 74 | 0 | 15 | — | — |
IA indicates immunoadsorption; PRE, prednisolone; MM, mycophenolate mofetil; CyA, cyclosporine A; EO, endocrine orbitopathy; MG, myasthenia gravis; SLE, systemic lupus erythematosus; and GB, Guillain-Barré syndrome.